Johns Hopkins Center for Psychedelic and Consciousness Research
Johns Hopkins Center for Psychedelic and Consciousness Research
Baltimore, Maryland, United States10 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Psilocybin Efficacy With or Without Pimavanserin Pretreatment | Healthy; Mood; Mood (Psychological Function); Well Being | Recruiting | Phase 1 / Phase 2 | 2026-10-01 | NCT07610135 | |
| Shortened LSD Intervention for Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Not yet recruiting | Phase 1 | 2026-09-22 | NCT07503002 | |
| Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) | Stress Disorders, Traumatic, acute stress disorder, post-traumatic stress disorder, psychiatric disorder | Recruiting | Phase 1 | 2026-09-04 | NCT06989957 | |
| Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Mild Cognitive Impairment, brain disorder, central nervous system disorder, cognitive disorder, dementia, depressive disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Early phase 1 | 2026-09-04 | NCT04123314 | |
| Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Early phase 1 | 2026-08-11 | NCT06656702 | |
| Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought | Healthy | Recruiting | Phase 1 / Phase 2 | 2026-07-23 | NCT05301608 | |
| Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, opiate dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 2 | 2026-07-17 | NCT06067737 | |
| A Study of Psilocybin for PTSD | Stress Disorders, Traumatic, acute stress disorder, post-traumatic stress disorder, psychiatric disorder | Active, not recruiting | Phase 1 | 2026-06-22 | NCT06407635 | |
| Psilocybin-assisted Treatment for Cannabis Use Disorder | Chemically-Induced Disorders, cannabis dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 1 | 2026-03-18 | NCT06660381 | |
| Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder | Alcohol Use Disorder, Chemically-Induced Disorders, alcohol-related disorders, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder, substance-related disorder | Active, not recruiting | Phase 2 | 2026-03-13 | NCT04620759 |